• / Free eNewsletters & Magazine
  • / My Account
Home>Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

09/29/2017

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

– Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa ® and Tagrisso ® refractory patients with MET amplification –

– Results to further validate Chi-Med’s scientific strategy of designing highly selective small molecule TKIs that can be safely and effectively used in combination regimens –

– Updated data through August 2017 will be reviewed on-site in three oral presentations –

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that non-small cell lung cancer (“NSCLC”) proof-of-concept clinical data on two of its novel tyrosine kinase inhibitors (“TKI”), savolitinib and fruquintinib, will be presented at the 18th World Conference on Lung Cancer (“WCLC”), to be held in Yokohama, Japan from October 15 to 18, 2017. The three oral presentations cover the following studies in epidermal growth factor receptor (“EGFR”)-mutant NSCLC patients:

Savolitinib plus Tagrisso ® (osimertinib) for EGFR-mutant MET amplified NSCLC patients after progression on prior EGFR-TKI, predominantly Iressa ® (gefitinib) or Tarceva ® (erlotinib)

The proof-of-concept TATTON B study demonstrated promising safety, tolerability, and efficacy of this combination. Data was not yet mature at abstract data cut-off (April 2017). The presentation will include data up to and including August 2017, including further patient enrolment, response confirmations, and duration of response results.

Title:   OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
Presenting Author: Myung-Ju Ahn
Authors: Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. Tsai, James Chih-Hsin Yang, Helena Yu, L. Horn, K. Lee, V. Haddad, M.M. Frigault, G. Ahmed, L. Yang, D. Ghiorghiu, Geoffrey R. Oxnard
Time & Location: Tuesday October 17, 2017, 11:20AM – 11:30AM, Room 301 + 302
Session: OA 09 – EGFR TKI Resistance (ID 663)

Savolitinib plus Iressa ® (gefitinib) for EGFR-mutant MET amplified NSCLC patients after progression on prior EGFR-TKI

©2017 Morningstar Advisor. All right reserved.